Ampreloxetine

Summary

Ampreloxetine (CHEMBL4297646) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including orthostatic hypotension and multiple system atrophy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 10
• Chemistry: 321.3 Da · C18H18F3NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297646
Name	Ampreloxetine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	46189893
Molecular formula	C18H18F3NO
Molecular weight	321.3
InChIKey	TZIALEBTHQWNAO-UHFFFAOYSA-N

SMILES: C1CNCCC1C2=CC=CC=C2COC3=C(C=C(C=C3F)F)F

IUPAC name: 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine

Also known as: Ampreloxetina, Ampreloxetine, Td-9855, TD-9855, AMPRELOXETINE

Parent form; salt/anhydrous children: CHEMBL4594277

Patent coverage: 11 distinct patent families (89 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
orthostatic hypotension	3	MONDO:0005469	EFO:0005252
multiple system atrophy	3	MONDO:0007803	EFO:1001050
Parkinson disease	3	MONDO:0005180	MONDO:0005180
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
fibromyalgia	2	MONDO:0005546	EFO:0005687

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	4
PHASE1	4
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05696717	PHASE3	ACTIVE_NOT_RECRUITING	Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT03750552	PHASE3	COMPLETED	Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT03829657	PHASE3	TERMINATED	Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT04095793	PHASE3	TERMINATED	Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
NCT01458340	PHASE2	COMPLETED	A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT02705755	PHASE2	COMPLETED	TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
NCT01924143	PHASE1	COMPLETED	TD-9855 Mass Balance Study
NCT03432793	PHASE1	COMPLETED	Drug-Drug Interaction (DDI) Study for TD-9855
NCT04200573	PHASE1	COMPLETED	Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
NCT04688632	PHASE1	COMPLETED	Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).